These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 30052144)

  • 21. Discovery of clinical candidate 1-(4-(3-(4-(1H-benzo[d]imidazole-2-carbonyl)phenoxy)pyrazin-2-yl)piperidin-1-yl)ethanone (AMG 579), a potent, selective, and efficacious inhibitor of phosphodiesterase 10A (PDE10A).
    Hu E; Chen N; Bourbeau MP; Harrington PE; Biswas K; Kunz RK; Andrews KL; Chmait S; Zhao X; Davis C; Ma J; Shi J; Lester-Zeiner D; Danao J; Able J; Cueva M; Talreja S; Kornecook T; Chen H; Porter A; Hungate R; Treanor J; Allen JR
    J Med Chem; 2014 Aug; 57(15):6632-41. PubMed ID: 25062128
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of Chirality of Crizotinib on Its MTH1 Protein Inhibitory Activity: Insight from Molecular Dynamics Simulations and Binding Free Energy Calculations.
    Niu Y; Pan D; Shi D; Bai Q; Liu H; Yao X
    PLoS One; 2015; 10(12):e0145219. PubMed ID: 26677850
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Structure guided design and kinetic analysis of highly potent benzimidazole inhibitors targeting the PDEδ prenyl binding site.
    Zimmermann G; Schultz-Fademrecht C; Küchler P; Murarka S; Ismail S; Triola G; Nussbaumer P; Wittinghofer A; Waldmann H
    J Med Chem; 2014 Jun; 57(12):5435-48. PubMed ID: 24884780
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Triazoloquinazolines as a novel class of phosphodiesterase 10A (PDE10A) inhibitors.
    Kehler J; Ritzen A; Langgård M; Petersen SL; Farah MM; Bundgaard C; Christoffersen CT; Nielsen J; Kilburn JP
    Bioorg Med Chem Lett; 2011 Jun; 21(12):3738-42. PubMed ID: 21602043
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fragment-based drug discovery of triazole inhibitors to block PDEδ-RAS protein-protein interaction.
    Chen D; Chen Y; Lian F; Chen L; Li Y; Cao D; Wang X; Chen L; Li J; Meng T; Huang M; Geng M; Shen J; Zhang N; Xiong B
    Eur J Med Chem; 2019 Feb; 163():597-609. PubMed ID: 30562696
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Decoding molecular mechanism of inhibitor bindings to CDK2 using molecular dynamics simulations and binding free energy calculations.
    Chen J; Pang L; Wang W; Wang L; Zhang JZH; Zhu T
    J Biomol Struct Dyn; 2020 Mar; 38(4):985-996. PubMed ID: 30843759
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Structure-based development of PDEδ inhibitors.
    Martín-Gago P; Fansa EK; Wittinghofer A; Waldmann H
    Biol Chem; 2017 May; 398(5-6):535-545. PubMed ID: 27935847
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of Novel PDEδ Degraders for the Treatment of KRAS Mutant Colorectal Cancer.
    Cheng J; Li Y; Wang X; Dong G; Sheng C
    J Med Chem; 2020 Jul; 63(14):7892-7905. PubMed ID: 32603594
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Binding mechanism of CDK5 with roscovitine derivatives based on molecular dynamics simulations and MM/PBSA methods.
    Dong K; Wang X; Yang X; Zhu X
    J Mol Graph Model; 2016 Jul; 68():57-67. PubMed ID: 27371933
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comparative study of binding affinities for 6,7-dimethoxy-4-pyrrolidylquinazolines as phosphodiesterase 10A inhibitors using the linear interaction energy method.
    Kjellgren ER; Glue OE; Reinholdt P; Meyer JE; Kongsted J; Poongavanam V
    J Mol Graph Model; 2015 Sep; 61():44-52. PubMed ID: 26188794
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BN/CC isosterism in borazaronaphthalenes towards phosphodiesterase 10A (PDE10A) inhibitors.
    Vlasceanu A; Jessing M; Kilburn JP
    Bioorg Med Chem; 2015 Aug; 23(15):4453-4461. PubMed ID: 26113188
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Case-specific performance of MM-PBSA, MM-GBSA, and SIE in virtual screening.
    Virtanen SI; Niinivehmas SP; Pentikäinen OT
    J Mol Graph Model; 2015 Nov; 62():303-318. PubMed ID: 26550792
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mapping the isoprenoid binding pocket of PDEdelta by a semisynthetic, photoactivatable N-Ras lipoprotein.
    Alexander M; Gerauer M; Pechlivanis M; Popkirova B; Dvorsky R; Brunsveld L; Waldmann H; Kuhlmann J
    Chembiochem; 2009 Jan; 10(1):98-108. PubMed ID: 18846587
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular dynamics insights for PI3K-δ inhibition & structure guided identification of novel PI3K-δ inhibitors.
    Srivastava S; Singh Choudhary B; Mehta P; Sukanya ; Sharma M; Malik R
    J Biomol Struct Dyn; 2019 Jun; 37(9):2404-2414. PubMed ID: 30047836
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Investigation of the binding mode of 1, 3, 4-oxadiazole derivatives as amide-based inhibitors for soluble epoxide hydrolase (sEH) by molecular docking and MM-GBSA.
    Karami L; Saboury AA; Rezaee E; Tabatabai SA
    Eur Biophys J; 2017 Jul; 46(5):445-459. PubMed ID: 27928588
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The molecular mechanism studies of chirality effect of PHA-739358 on Aurora kinase A by molecular dynamics simulation and free energy calculations.
    Cheng Y; Cui W; Chen Q; Tung CH; Ji M; Zhang F
    J Comput Aided Mol Des; 2011 Feb; 25(2):171-80. PubMed ID: 21222017
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Unique Sub-Pocket for Improvement of Selectivity of Phosphodiesterase Inhibitors in CNS.
    Wang Y; Ke H
    Adv Neurobiol; 2017; 17():463-471. PubMed ID: 28956343
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular dynamics-based discovery of novel phosphodiesterase-9A inhibitors with non-pyrazolopyrimidinone scaffolds.
    Li Z; Lu X; Feng LJ; Gu Y; Li X; Wu Y; Luo HB
    Mol Biosyst; 2015 Jan; 11(1):115-25. PubMed ID: 25328054
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Particle swarm optimization and genetic algorithm as feature selection techniques for the QSAR modeling of imidazo[1,5-a]pyrido[3,2-e]pyrazines, inhibitors of phosphodiesterase 10A.
    Goodarzi M; Saeys W; Deeb O; Pieters S; Vander Heyden Y
    Chem Biol Drug Des; 2013 Dec; 82(6):685-96. PubMed ID: 23906083
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular docking and molecular dynamics studies reveal structural basis of inhibition and selectivity of inhibitors EGCG and OSU-03012 toward glucose regulated protein-78 (GRP78) overexpressed in glioblastoma.
    Bhattacharjee R; Devi A; Mishra S
    J Mol Model; 2015 Oct; 21(10):272. PubMed ID: 26419972
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.